FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 348:1199-1200 March 27, 2003 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Cools, J. PubMed Citation

Patients with sustained high-grade eosinophilia without an evident cause usually receive the diagnosis of hypereosinophilic syndrome, a high-sounding term that only masks our ignorance. Apart from the consistent presence of hypereosinophilia, the clinical picture of the hypereosinophilic syndrome varies. In some cases, the toxic contents of tissue-invasive eosinophils (see electron micrograph) cause heart failure, pulmonary lesions, and harm to other organs. In other cases, urticaria and itchy nodules in the skin dominate the clinical picture. The hypereosinophilic syndrome is a rare disorder, yet as Cools et al. tell us in this issue of the Journal (pages 1201–1214), it carries . . . [Full Text of this Article]

This article has been cited by other articles:

• Rondoni, M., Ottaviani, E., Piccaluga, P. P., Paolini, S., Merante, S., Cilloni, D., Malagola, M., Palmisano, M., Grafone, T., Messa, F., Buccisano, F., Tiribelli, M., Pane, F., Saglio, G., Martinelli, G., Baccarani, M. (2006). FIP1L1-PDGFRalpha Positive Hypereosinophilic Syndrome (HES). The Response to Imatinib (IM) Is Durable. A Report of 21 Patients with a Follow-Up of 12 to 67 Months.. ASH ANNUAL MEETING ABSTRACTS 108: 2700-2700 [Abstract]  
• Kankaanranta, H., Ilmarinen, P., Zhang, X., Nissinen, E., Moilanen, E. (2006). Antieosinophilic Activity of Orazipone. Mol. Pharmacol. 69: 1861-1870 [Abstract] [Full Text]  
• Ye, B., Skates, S., Mok, S. C., Horick, N. K., Rosenberg, H. F., Vitonis, A., Edwards, D., Sluss, P., Han, W. K., Berkowitz, R. S., Cramer, D. W. (2006). Proteomic-Based Discovery and Characterization of Glycosylated Eosinophil-Derived Neurotoxin and COOH-Terminal Osteopontin Fragments for Ovarian Cancer in Urine. Clin. Cancer Res. 12: 432-441 [Abstract] [Full Text]  
• Cheng, T.-I, Cheng, T.-J., Chiang, S. C (2004). Association of aspirin with eosinophilia in peripheral blood. The Annals of Pharmacotherapy 38: 2172-2173 [Full Text]  
• Huang, M. S., Hasserjian, R. P. (2004). Case 19-2004 - A 12-Year-Old Boy with Fatigue and Eosinophilia. NEJM 350: 2604-2612 [Full Text]  
• Smith, K. J., Jacobson, E., Hamza, S., Skelton, H. (2004). Unexplained Hypereosinophilia and the Need for Cytogenetic and Molecular Genetic Analyses. Arch Dermatol 140: 584-588 [Abstract] [Full Text]  
• Mohi, M. G., Boulton, C., Gu, T.-L., Sternberg, D. W., Neuberg, D., Griffin, J. D., Gilliland, D. G., Neel, B. G. (2004). Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc. Natl. Acad. Sci. USA 101: 3130-3135 [Abstract] [Full Text]  
• Roufosse, F. E., Goldman, M., Cogan, E., Gilliland, D. G., Stone, R. M., Coutre, S. E. (2003). Hypereosinophilic Syndrome. NEJM 348: 2687-2687 [Full Text]